Progress in neuroprotection in Parkinson’s disease
Identifieur interne : 000C96 ( Main/Exploration ); précédent : 000C95; suivant : 000C97Progress in neuroprotection in Parkinson’s disease
Auteurs : A. H. V. Schapira [Royaume-Uni]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2008-04.
English descriptors
- KwdEn :
Abstract
Slowing or aborting the progress of neurodegeneration in Parkinson’s disease (PD) remains the most important unmet need of this disorder. There are several recent developments in trial design and also in drugs under investigation for possible neuroprotective effect. Emphasis has been placed on clinical as opposed to imaging end‐points and these include change in a clinical rating scale, e.g. United Parkinson's disease Rating Scale (UPDRS), or time to additional therapy. The introduction of the delayed‐start, or wash‐in, trial design adds an additional dimension to drug evaluation for neuroprotection. Compounds that have been recently tested in clinical trial include the monoamine oxidase‐B inhibitor rasagiline, the anti‐apoptotic agents TCH346 and CEP1347, and the promitochondrial agent creatine. The dopamine agonists have been evaluated for a neuroprotective effect using imaging end‐points. Perhaps the most important and simplest concept for neuroprotection has been the theory that early dopaminergic support for the degenerating dopaminergic system per se provides significant long‐term clinical benefit for PD patients.
Url:
DOI: 10.1111/j.1468-1331.2008.02055.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progress in neuroprotection in Parkinson’s disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB0EFA6AB8B6D39793D0E17620E44A128BBC9AC0</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-1331.2008.02055.x</idno><idno type="url">https://api.istex.fr/document/BB0EFA6AB8B6D39793D0E17620E44A128BBC9AC0/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000070</idno><idno type="wicri:Area/Main/Curation">000058</idno><idno type="wicri:Area/Main/Exploration">000C96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Progress in neuroprotection in Parkinson’s disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-04">2008-04</date><biblScope unit="volume">15</biblScope><biblScope unit="supplement">s1</biblScope><biblScope unit="page" from="5">5</biblScope><biblScope unit="page" to="13">13</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">BB0EFA6AB8B6D39793D0E17620E44A128BBC9AC0</idno><idno type="DOI">10.1111/j.1468-1331.2008.02055.x</idno><idno type="ArticleID">ENE2055</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>apoptosis</term><term>dopamine agonists</term><term>monoamine oxidase inhibitors</term><term>neuroprotection</term><term>propargylamines</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Slowing or aborting the progress of neurodegeneration in Parkinson’s disease (PD) remains the most important unmet need of this disorder. There are several recent developments in trial design and also in drugs under investigation for possible neuroprotective effect. Emphasis has been placed on clinical as opposed to imaging end‐points and these include change in a clinical rating scale, e.g. United Parkinson's disease Rating Scale (UPDRS), or time to additional therapy. The introduction of the delayed‐start, or wash‐in, trial design adds an additional dimension to drug evaluation for neuroprotection. Compounds that have been recently tested in clinical trial include the monoamine oxidase‐B inhibitor rasagiline, the anti‐apoptotic agents TCH346 and CEP1347, and the promitochondrial agent creatine. The dopamine agonists have been evaluated for a neuroprotective effect using imaging end‐points. Perhaps the most important and simplest concept for neuroprotection has been the theory that early dopaminergic support for the degenerating dopaminergic system per se provides significant long‐term clinical benefit for PD patients.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BB0EFA6AB8B6D39793D0E17620E44A128BBC9AC0
|texte= Progress in neuroprotection in Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |